Clinical Application of 18F-PEG3-FPN PET Imaging in Diagnosis and Staging of Malignant Melanoma
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study is a diagnostic study. Patients and healthy volunteers were recruited from
clinically suspected or confirmed melanoma patients to undergo 18F-PEG3-FPN PET/MR or PET/CT
imaging to observe the response of the subjects after drug injection, and evaluate the
efficacy of 18F-PEG3-FPN PET imaging in the diagnosis and staging of melanoma compared with
18F-FDG PET imaging. PET/CT imaging was performed in patients with contraindications to MR.
The subjects underwent 18F-PEG3-FPN and 18F-FDG PET/MR or PET/CT imaging at an interval of
two days, respectively. The general information, clinical data, blood routine, liver and
kidney function indexes, 18F-PEG3-FPN and 18F-FDG PET/MR or PET/CT imaging results and other
imaging data of the patients and volunteers were collected, and the histopathology of biopsy
or surgical specimen was taken as the final diagnostic criteria. This study plans to set the
sample size as 50 cases.